UK Patients with Moderately to Severely Active UC Gain Access to New Drugs

UK Patients with Moderately to Severely Active UC Gain Access to New Drugs
Patients with moderately to severely active ulcerative colitis, residing in the United Kingdom, now have access to several new drugs thanks to the Final Appraisal Document (FAD) from the National Institute for Health and Care Excellence (NICE). REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI®(golimumab) will be available to UC patients who have not achieved adequate treatment response to traditional therapy,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *